NasdaqGS - Nasdaq Real Time Price USD
Mind Medicine (MindMed) Inc. (MNMD)
7.48
+0.22
+(3.03%)
At close: June 2 at 4:00:00 PM EDT
7.33
-0.15
(-2.01%)
After hours: June 2 at 7:53:14 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Robert Barrow | CEO & Director | 997.01k | -- | 1989 |
| Mr. Mark R. Sullivan J.D. | Chief Legal Officer & Corporate Secretary | 638.61k | -- | 1971 |
| Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer | 703.32k | -- | 1980 |
| Dr. Scott M. Freeman M.D. | Co-Founder & Clinical Advisor | 313.23k | -- | 1957 |
| Mr. Leonard Latchman | Co-Founder | -- | -- | -- |
| Mr. Peter Mack | Senior Vice President of Pharmaceutical Development & Operations | -- | -- | -- |
| Ms. Carrie F. Liao CPA, CGMA | VP & Chief Accounting Officer | -- | -- | 1966 |
| Ms. Beth Calitri | Vice President of Corporate Communications | -- | -- | -- |
| Ms. Stephanie Fagan | Chief Corporate Affairs Officer | -- | -- | -- |
| Dr. Gregg Pratt Ph.D. | Chief Regulatory & Quality Assurance Officer | -- | -- | -- |
Mind Medicine (MindMed) Inc.
One World Trade Center
Suite 8500
New York, NY 10007
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 74
Description
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Corporate Governance
Mind Medicine (MindMed) Inc.’s ISS Governance QualityScore as of June 1, 2025 is 4. The pillar scores are Audit: 7; Board: 3; Shareholder Rights: 4; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 11, 2025 at 12:30 PM UTC - August 15, 2025 at 12:30 PM UTC
Mind Medicine (MindMed) Inc. Earnings Date
Recent Events
Related Tickers
ATAI Atai Life Sciences N.V.
2.4900
+7.79%
CYBN Cybin Inc.
8.10
+1.76%
CYBN.NE Cybin Inc.
11.03
+1.10%
GHRS GH Research PLC
11.56
-3.91%
DNA Ginkgo Bioworks Holdings, Inc.
7.13
+2.59%
NRXP NRx Pharmaceuticals, Inc.
2.6800
+1.52%
ATYR aTyr Pharma, Inc.
4.7500
+6.26%
RCKT Rocket Pharmaceuticals, Inc.
2.7700
+10.36%
ABCL AbCellera Biologics Inc.
2.1400
+5.94%
CRSP CRISPR Therapeutics AG
36.95
+1.82%